tokens: There is also a potential pharmacokinetic interaction with quinidine due to the fact that clomipramine is metabolised by CYP2D6 " in vivo " ) , diuretics ( due to the potential for hypokalaemia ( low blood potassium ) to develop which increases the risk for QT interval prolongation and torsades de pointes ) , the selective serotonin reuptake inhibitors ( SSRIs ; due to both potential additive serotonergic effects leading to serotonin syndrome and the potential for a pharmacokinetic interaction with the SSRIs that inhibit CYP2D6 [ e.g. fluoxetine and paroxetine ] ) and serotonergic agents such as triptans , other tricyclic antidepressants , tramadol , etc .